Ratings by Piper Sandler (Edward Tenthoff)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/4/2026 | Immunitybio Inc | IBRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2026 | Cardiff Oncology | CRDF | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2026 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2026 | Century Therapeutics | IPSC | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2026 | Immunitybio Inc | IBRX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2026 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/14/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2026 | Acrivon Therapeutics Inc | ACRV | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Capricor Therapeutics | CAPR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2025 | Capricor Therapeutics | CAPR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/1/2025 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/21/2025 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2025 | Inovio Pharmaceuticals | INO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2025 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | (N/A) |
|
Details | ||
| 9/29/2025 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/23/2025 | Skye Bioscience | SKYE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2025 | CAMP4 Therapeutics Corp | CAMP | Maintain | Overweight (N/A) |
|
Details | ||
| 9/2/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/1/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2025 | NextCure Inc. | NXTC | Maintain | Overweight (N/A) |
|
Details | ||
| 7/9/2025 | Inovio Pharmaceuticals | INO | New Coverage | Overweight (N/A) |
1.33 (1.74) |
30.83% | Details | |
| 6/16/2025 | Sutro Biopharma | STRO | Upgrade | Overweight (Neutral) |
0.81 (25.29) |
3022.22% | Details | |
| 6/3/2025 | Biomea Fusion Inc. | BMEA | New Coverage | Overweight (N/A) |
1.44 (1.39) |
-3.47% | Details | |
| 6/2/2025 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/20/2025 | Immunitybio Inc | IBRX | Upgrade | Overweight (Neutral) |
2.80 (8.67) |
209.64% | Details | |
| 5/5/2025 | Acrivon Therapeutics Inc | ACRV | New Coverage | Overweight (N/A) |
1.41 (1.55) |
9.93% | Details | |
| 4/14/2025 | LENZ Therapeutics Inc | LENZ | New Coverage | Overweight (N/A) |
20.26 (11.67) |
-42.4% | Details | |
| 4/14/2025 | Cardiff Oncology | CRDF | New Coverage | Overweight (N/A) |
2.47 (1.88) |
-23.89% | Details | |
| 4/14/2025 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
0.53 (4.68) |
783.02% | Details | |
| 3/20/2025 | Century Therapeutics | IPSC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2025 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2025 | Sutro Biopharma | STRO | Downgrade | Neutral (Overweight) |
1.25 (0.81) |
-35.2% | Details | |
| 3/12/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2025 | Capricor Therapeutics | CAPR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2025 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2025 | Mesoblast Limited | MESO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/30/2024 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/30/2024 | Century Therapeutics | IPSC | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2024 | Mesoblast Limited | MESO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2024 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2024 | Capricor Therapeutics | CAPR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2024 | Xencor, Inc. | XNCR | Upgrade | Overweight (Neutral) |
25.62 (11.32) |
-55.82% | Details | |
| 12/2/2024 | Poseida Therapeutics, Inc | PSTX | Downgrade | Neutral (Overweight) |
9.33 (9.50) |
1.82% | Details | |
| 11/18/2024 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2024 | Omega Therapeutics | OMGA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2024 | Tempest Therapeutics | TPST | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2024 | Rapt Therapeutics | RAPT | Downgrade | Neutral (Overweight) |
2.89 (32.42) |
1021.8% | Details | |
| 11/5/2024 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Overweight (N/A) |
10.05 (4.20) |
-58.21% | Details | |
| 10/24/2024 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/23/2024 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2024 | Capricor Therapeutics | CAPR | New Coverage | Overweight (N/A) |
18.49 (27.90) |
50.89% | Details | |
| 10/11/2024 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2024 | Poseida Therapeutics, Inc | PSTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2024 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2024 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 9/23/2024 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2024 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2024 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2024 | Skye Bioscience | SKYE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2024 | Mesoblast Limited | MESO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2024 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2024 | aTyr Pharma | LIFE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2024 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2024 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2024 | Gritstone bio | GRTS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2024 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/23/2024 | Mesoblast Limited | MESO | Upgrade | Overweight (Neutral) |
7.55 (15.85) |
109.93% | Details | |
| 6/28/2024 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2024 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/26/2024 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Century Therapeutics | IPSC | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Fate Therapeutics | FATE | Upgrade | Overweight (Neutral) |
3.76 (1.33) |
-64.63% | Details | |
| 6/6/2024 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2024 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2024 | NextCure Inc. | NXTC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/30/2024 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2024 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/12/2024 | Century Therapeutics | IPSC | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2024 | Omega Therapeutics | OMGA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2024 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2024 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2024 | Skye Bioscience | SKYE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2024 | Milestone Pharmaceuticals | MIST | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2024 | Xencor, Inc. | XNCR | Downgrade | Neutral (Overweight) |
26.52 (25.62) |
-3.39% | Details | |
| 2/27/2024 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2024 | Skye Bioscience | SKYE | New Coverage | Overweight (N/A) |
3.69 (0.72) |
-80.49% | Details | |
| 1/26/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2024 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/21/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/11/2023 | Poseida Therapeutics, Inc | PSTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2023 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2023 | Gamida Cell Ltd. | GMDA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2023 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | POINT Biopharma Global Inc. | PNT | Downgrade | Neutral (Overweight) |
12.95 (12.50) |
-3.47% | Details | |
| 10/3/2023 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/28/2023 | Gritstone Oncology | GRTS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | Galera Therapeutics | GRTX | Downgrade | Neutral (Overweight) |
2.11 (0.15) |
-92.89% | Details | |
| 8/9/2023 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2023 | Mesoblast Limited | MESO | Downgrade | Neutral (Overweight) |
3.99 (15.85) |
297.24% | Details | |
| 7/20/2023 | aTyr Pharma | LIFE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/11/2023 | aTyr Pharma | LIFE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2023 | Gamida Cell Ltd. | GMDA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/27/2023 | Jounce Therapeutics | JNCE | Downgrade | Neutral (N/A) |
1.51 (1.88) |
24.5% | Details | |
| 3/23/2023 | Tempest Therapeutics | TPST | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Infinity Pharmaceutical | INFI | Downgrade | Neutral (Overweight) |
0.55 (0.04) |
-92.73% | Details | |
| 2/23/2023 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2023 | Galera Therapeutics | GRTX | New Coverage | Overweight (N/A) |
1.59 (0.15) |
-90.57% | Details | |
| 2/15/2023 | aTyr Pharma | LIFE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/10/2023 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2023 | Century Therapeutics | IPSC | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2023 | Fate Therapeutics | FATE | Downgrade | Neutral (Overweight) |
11.12 (3.76) |
-66.19% | Details | |
| 1/5/2023 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2023 | Jounce Therapeutics | JNCE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2022 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/16/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2022 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2022 | X4 Pharmaceuticals | XFOR | New Coverage | Overweight (N/A) |
0.99 (3.76) |
279.8% | Details | |
| 12/9/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2022 | Aravive Inc. | ARAV | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2022 | NextCure Inc. | NXTC | Maintain | (N/A) |
|
Details | ||
| 10/31/2022 | Gritstone Oncology | GRTS | New Coverage | Overweight (N/A) |
2.41 (0.03) |
-98.76% | Details | |
| 10/3/2022 | Gamida Cell Ltd. | GMDA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/20/2022 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/19/2022 | POINT Biopharma Global Inc. | PNT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2022 | POINT Biopharma Global Inc. | PNT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/6/2022 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/6/2022 | Mesoblast Limited | MESO | New Coverage | Overweight (N/A) |
2.93 (15.85) |
440.96% | Details | |
| 8/26/2022 | PureTech Health | PRTC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2022 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2022 | aTyr Pharma | LIFE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2022 | Poseida Therapeutics, Inc | PSTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2022 | ChemoCentryx | CCXI | Downgrade | Neutral (Overweight) |
24.11 (10.16) |
-57.86% | Details | |
| 7/25/2022 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/28/2022 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Omega Therapeutics | OMGA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | NextCure Inc. | NXTC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Jounce Therapeutics | JNCE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Infinity Pharmaceutical | INFI | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2022 | aTyr Pharma | LIFE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2022 | Century Therapeutics | IPSC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2022 | Tempest Therapeutics | TPST | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2022 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2022 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2022 | Milestone Pharmaceuticals | MIST | Upgrade | Overweight (Neutral) |
7.29 (1.58) |
-78.33% | Details | |
| 3/30/2022 | Infinity Pharmaceutical | INFI | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2022 | Legand Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/31/2022 | Kaleido Biosciences Inc. | KLDO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/11/2022 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/10/2022 | Tempest Therapeutics | TPST | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2022 | Alnylam Pharmaceuticals | ALNY | Upgrade | Overweight (Neutral) |
171.03 (320.66) |
87.49% | Details | |
| 12/21/2021 | Legand Biotech Corp. | LEGN | New Coverage | Overweight (N/A) |
46.75 (18.97) |
-59.42% | Details | |
| 11/29/2021 | argenx SE | ARGX | Upgrade | Overweight (Neutral) |
276.91 (717.80) |
159.22% | Details | |
| 11/16/2021 | Gamida Cell Ltd. | GMDA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2021 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2021 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/15/2021 | Moderna | MRNA | Upgrade | Overweight (Neutral) |
321.50 (52.52) |
-83.66% | Details | |
| 10/12/2021 | Poseida Therapeutics, Inc | PSTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2021 | ChemoCentryx | CCXI | Upgrade | Overweight (Neutral) |
19.60 (10.16) |
-48.16% | Details | |
| 10/4/2021 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 9/21/2021 | aTyr Pharma | LIFE | New Coverage | Overweight (N/A) |
10.31 (13.16) |
27.64% | Details | |
| 8/25/2021 | PureTech Health | PRTC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2021 | Omega Therapeutics | OMGA | New Coverage | Overweight (N/A) |
21.83 (0.14) |
-99.36% | Details | |
| 8/9/2021 | NextCure Inc. | NXTC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2021 | Moderna | MRNA | Downgrade | Neutral (Overweight) |
419.05 (52.52) |
-87.47% | Details | |
| 8/4/2021 | Alnylam Pharmaceuticals | ALNY | Downgrade | Neutral (Overweight) |
177.96 (320.66) |
80.19% | Details | |
| 7/30/2021 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2021 | Infinity Pharmaceutical | INFI | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2021 | POINT Biopharma Global Inc. | PNT | New Coverage | Overweight (N/A) |
8.45 (12.50) |
47.93% | Details | |
| 7/19/2021 | Monte Rosa Therapeutics | GLUE | New Coverage | Overweight (N/A) |
19.12 (17.80) |
-6.9% | Details | |
| 7/13/2021 | Century Therapeutics | IPSC | New Coverage | Overweight (N/A) |
27.61 (2.56) |
-90.73% | Details | |
| 7/6/2021 | Tempest Therapeutics | TPST | New Coverage | Overweight (N/A) |
11.22 (2.31) |
-79.41% | Details | |
| 6/21/2021 | Rapt Therapeutics | RAPT | New Coverage | Overweight (N/A) |
33.40 (58.02) |
73.71% | Details | |
| 6/14/2021 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/8/2021 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 6/7/2021 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2021 | Poseida Therapeutics, Inc | PSTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Bicycle Therapeutics | BCYC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | ChemoCentryx | CCXI | Downgrade | Neutral (Overweight) |
27.49 (19.60) |
-28.7% | Details | |
| 4/12/2021 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 3/15/2021 | Jounce Therapeutics | JNCE | New Coverage | Overweight (N/A) |
13.87 (1.88) |
-86.45% | Details | |
| 2/18/2021 | Infinity Pharmaceutical | INFI | New Coverage | Overweight (N/A) |
4.18 (0.04) |
-99.04% | Details | |
| 2/17/2021 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2021 | Gamida Cell Ltd. | GMDA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/9/2021 | Kaleido Biosciences Inc. | KLDO | New Coverage | Overweight (N/A) |
11.21 (0.00) |
-100% | Details | |
| 2/5/2021 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2021 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2021 | Agile Therapeutics | AGRX | Downgrade | Neutral (Overweight) |
2.81 (1.51) |
-46.26% | Details | |
| 1/11/2021 | Chiasma | CHMA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2020 | Sutro Biopharma | STRO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2020 | Bicycle Therapeutics | BCYC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/15/2020 | Fulcrrum Therapeutics | FULC | New Coverage | Overweight (N/A) |
11.27 (8.17) |
-27.51% | Details | |
| 10/8/2020 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2020 | Matinas BioPharma Holdings Inc. | MTNB | New Coverage | Overweight (N/A) |
0.80 (0.60) |
-25% | Details | |
| 8/24/2020 | Proteostasis Therapeutics | PTI | New Coverage | Neutral (Overweight) |
1.30 (1.19) |
-8.46% | Details | |
| 8/18/2020 | Seres Therapeutics | MCRB | New Coverage | Overweight (N/A) |
27.26 (9.13) |
-66.51% | Details | |
| 7/15/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2020 | Arrowhead Research | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/29/2020 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2020 | Alpine Immune Sciences | ALPN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/9/2020 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2020 | AVEO Pharmaceuticals | AVEO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/26/2020 | Gamida Cell Ltd. | GMDA | New Coverage | Overweight (N/A) |
5.30 (0.03) |
-99.43% | Details | |
| 5/18/2020 | ChemoCentryx | CCXI | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2020 | Aeglea Biotherapeutics | AGLE | New Coverage | Overweight (N/A) |
7.77 (12.01) |
54.57% | Details | |
| 4/17/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/6/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/24/2020 | Milestone Pharmaceuticals | MIST | Downgrade | Neutral (Overweight) |
12.02 (1.58) |
-86.86% | Details | |
| 3/11/2020 | Proteostasis Therapeutics | PTI | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2020 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2020 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2020 | Bicycle Therapeutics | BCYC | Maintain | Overweight (N/A) |
|
Details | ||
| 1/31/2020 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2020 | Matinas BioPharma Holdings Inc. | MTNB | New Coverage | Overweight (N/A) |
1.51 (0.60) |
-60.26% | Details | |
| 1/21/2020 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2020 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2020 | IGM Biosciences | IGMS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2020 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/27/2019 | Spring Bank Pharmaceuticals | SBPH | Downgrade | Neutral (Overweight) |
3.61 (1.21) |
-66.48% | Details | |
| 12/17/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/11/2019 | ContraFect Corp. | CFRX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2019 | Arrowhead Research | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2019 | Aslan Pharma | ASLN | Upgrade | Overweight (Neutral) |
3.82 (0.60) |
-84.29% | Details | |
| 11/26/2019 | ChemoCentryx | CCXI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2019 | Opko Health | OPK | New Coverage | Overweight (N/A) |
1.60 (1.18) |
-26.25% | Details | |
| 11/21/2019 | Aravive Inc. | ARAV | Maintain | Overweight (N/A) |
|
Details | ||
| 11/20/2019 | Aravive Inc. | ARAV | Maintain | Overweight (N/A) |
|
Details | ||
| 11/20/2019 | NextCure Inc. | NXTC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2019 | Alpine Immune Sciences | ALPN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2019 | Marker Therapeutics | MRKR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2019 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2019 | Aslan Pharma | ASLN | Downgrade | Neutral (Overweight) |
2.08 (3.82) |
83.65% | Details | |
| 10/31/2019 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2019 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 10/14/2019 | IGM Biosciences | IGMS | New Coverage | Overweight (N/A) |
17.43 (1.27) |
-92.71% | Details | |
| 9/16/2019 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2019 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2019 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/10/2019 | AVEO Pharmaceuticals | AVEO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/5/2019 | NextCure Inc. | NXTC | Maintain | Overweight (N/A) |
|
Details | ||
| 9/3/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/28/2019 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2019 | Synlogic Inc. | SYBX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2019 | Arrowhead Research | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/1/2019 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2019 | Chiasma | CHMA | New Coverage | Overweight (N/A) |
5.56 (3.79) |
-31.83% | Details | |
| 7/15/2019 | Synlogic Inc. | SYBX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/5/2019 | Celyad SA | CYAD | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2019 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2019 | Fate Therapeutics | FATE | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/27/2019 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 6/21/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2019 | Array BioPharma | ARRY | Downgrade | Neutral (Overweight) |
29.59 (6.81) |
-76.99% | Details | |
| 6/17/2019 | Bicycle Therapeutics | BCYC | New Coverage | Overweight (N/A) |
12.40 (5.19) |
-58.15% | Details | |
| 6/12/2019 | Synlogic Inc. | SYBX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/7/2019 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/4/2019 | Array BioPharma | ARRY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2019 | NextCure Inc. | NXTC | New Coverage | Overweight (N/A) |
19.18 (12.39) |
-35.4% | Details | |
| 6/3/2019 | Milestone Pharmaceuticals | MIST | New Coverage | Overweight (N/A) |
21.16 (12.02) |
-43.19% | Details | |
| 5/21/2019 | Array BioPharma | ARRY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2019 | Aravive Inc. | ARAV | New Coverage | Overweight (N/A) |
6.13 (0.04) |
-99.35% | Details | |
| 4/15/2019 | Arrowhead Research | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2019 | Syros Pharmaceuticals | SYRS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/20/2019 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/15/2019 | Tetraphase Pharmaceuticals | TTPH | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2019 | Zafgen | ZFGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2019 | Novavax | NVAX | Downgrade | Underweight (Overweight) |
2.13 (9.98) |
368.54% | Details | |
| 2/11/2019 | ChemoCentryx | CCXI | New Coverage | Overweight (N/A) |
11.06 (10.16) |
-8.14% | Details | |
| 2/8/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2019 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2019 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/15/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2019 | Marina Biotech | MRNA | New Coverage | Overweight (N/A) |
15.27 (52.52) |
243.94% | Details | |
| 12/3/2018 | Marker Therapeutics | MRKR | Upgrade | Overweight (Neutral) |
7.07 (1.38) |
-80.48% | Details | |
| 11/26/2018 | Novavax | NVAX | Upgrade | Overweight (Neutral) |
1.71 (2.13) |
24.56% | Details | |
| 11/15/2018 | Aptevo Therapeutics | APVO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2018 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2018 | Proteostasis Therapeutics | PTI | New Coverage | Overweight (N/A) |
5.35 (1.30) |
-75.7% | Details | |
| 10/25/2018 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2018 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/22/2018 | Marker Therapeutics | MRKR | New Coverage | Neutral (N/A) |
8.63 (7.07) |
-18.08% | Details | |
| 10/22/2018 | Arvinas Inc. | ARVN | New Coverage | Overweight (N/A) |
15.45 (13.60) |
-11.97% | Details | |
| 10/22/2018 | Sutro Biopharma | STRO | New Coverage | Overweight (N/A) |
14.55 (25.29) |
73.81% | Details | |
| 10/12/2018 | Tetraphase Pharmaceuticals | TTPH | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2018 | aTyr Pharma | LIFE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/5/2018 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/4/2018 | Arrowhead Research | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2018 | Alpine Immune Sciences | ALPN | New Coverage | Overweight (N/A) |
6.39 (64.97) |
916.74% | Details | |
| 9/25/2018 | Fate Therapeutics | FATE | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/24/2018 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/18/2018 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2018 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/6/2018 | Arrowhead Research | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 9/5/2018 | Vericel Corporation | VCEL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/22/2018 | AVEO Pharmaceuticals | AVEO | Maintain | Overweight (Overweight) |
|
Details |
